

Pharmacology of phosphodiesterase-5 inhibitors

International Journal of Clinical Practice

56, 453-9

Citation Report

#	ARTICLE	IF	CITATIONS
1	To the Editor of Nature Reviews Drug Discovery. Nature Reviews Drug Discovery, 2002, 1, 740-740.	21.5	0
2	In response to the letter of Corbin and Sweeney. Nature Reviews Drug Discovery, 2002, 1, 740-740.	21.5	0
3	Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists. Current Urology Reports, 2003, 4, 457-465.	1.0	78
4	Three-Dimensional Structures of PDE4D in Complex with Roliprams and Implication on Inhibitor Selectivity. Structure, 2003, 11, 865-873.	1.6	118
5	Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: A review. Pediatric Pulmonology, 2003, 36, 529-535.	1.0	139
6	Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature, 2003, 425, 98-102.	13.7	258
7	Editorial: Membrane Bound Guanylyl Cyclase as a Potential Molecular Target for the Treatment of Erectile Dysfunction. Journal of Urology, 2003, 169, 1923-1923.	0.2	4
8	Molecular Biology and Pharmacology of PDE5 Inhibitor Therapy for Erectile Dysfunction. Journal of Andrology, 2003, 24, S38-41.	2.0	40
9	An Update on the PDE5 Inhibitors (PDE5 inhibitors). Journal of Andrology, 2003, 24, S52-8.	2.0	18
10	Cyclic Nucleotide Phosphodiesterase 5 and Sildenafil: Promises Realized. Molecular Pharmacology, 2003, 63, 1209-1211.	1.0	20
11	Cyclic Nucleotide Phosphodiesterase Activity, Expression, and Targeting in Cells of the Cardiovascular System. Molecular Pharmacology, 2003, 64, 533-546.	1.0	289
12	Cialis (tadalafil): a new treatment for erectile dysfunction. British Journal of Hospital Medicine, 2003, 64, 589-592.	0.3	2
13	Androgens Regulate Phosphodiesterase Type 5 Expression and Functional Activity in Corpora Cavernosa. Endocrinology, 2004, 145, 2253-2263.	1.4	324
14	Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 9624-9629.	3.3	92
15	Crystal Structures of Phosphodiesterases 4 and 5 in Complex with Inhibitor 3-Isobutyl-1-methylxanthine Suggest a Conformation Determinant of Inhibitor Selectivity. Journal of Biological Chemistry, 2004, 279, 13095-13101.	1.6	116
16	Emerging Pharmacologic Approaches for the Treatment of Lower Urinary Tract Disorders. Journal of Pharmacology and Experimental Therapeutics, 2004, 308, 797-804.	1.3	25
17	Ectopic Expression of Bovine Type 5 Phosphodiesterase Confers a Renal Phenotype in Drosophila. Journal of Biological Chemistry, 2004, 279, 8159-8168.	1.6	35
18	Effect of caffeine on response of rabbit isolated corpus cavernosum to high K ⁺ solution, noradrenaline and transmural electrical stimulation. Clinical and Experimental Pharmacology and Physiology, 2004, 31, 82-85.	0.9	6

#	ARTICLE	IF	CITATIONS
19	Pharmacotherapy for Erectile Dysfunction. <i>Journal of Sexual Medicine</i> , 2004, 1, 128-140.	0.3	34
20	Duration of Action of Sildenafil Citrate in Men with Erectile Dysfunction. <i>Journal of Sexual Medicine</i> , 2004, 1, 179-184.	0.3	46
21	Structural Basis for the Activity of Drugs that Inhibit Phosphodiesterases. <i>Structure</i> , 2004, 12, 2233-2247.	1.6	360
22	Effects of phosphodiesterase inhibition on cortical spreading depression and associated changes in extracellular cyclic GMP. <i>Biochemical Pharmacology</i> , 2004, 67, 1619-1627.	2.0	16
23	Differential inhibitor sensitivity between human recombinant and native photoreceptor cGMP-phosphodiesterases (PDE6s). <i>Biochemical Pharmacology</i> , 2004, 68, 867-873.	2.0	18
24	Therapy of ED: PDE-5 Inhibitors. <i>Endocrine</i> , 2004, 23, 135-142.	2.2	27
25	Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles. <i>Clinical Cardiology</i> , 2004, 27, 14-19.	0.7	57
26	Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2004, 44, 1488-1496.	1.2	134
27	The effect of selective phosphodiesterase inhibitors, alone and in combination, on a murine model of allergic asthma. <i>Respiratory Research</i> , 2004, 5, 4.	1.4	24
29	Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5). <i>Neurochemistry International</i> , 2004, 45, 859-863.	1.9	81
30	DA-8159 has erectile potentials much longer than the plasma half-life in a conscious rabbit model. <i>Life Sciences</i> , 2004, 75, 1075-1083.	2.0	8
31	Binding of Tritiated Sildenafil, Tadalafil, or Vardenafil to the Phosphodiesterase-5 Catalytic Site Displays Potency, Specificity, Heterogeneity, and cGMP Stimulation. <i>Molecular Pharmacology</i> , 2004, 66, 144-152.	1.0	168
32	Tadalafil: a long-acting PDE5 inhibitor for the management of erectile dysfunction. <i>Therapy: Open Access in Clinical Medicine</i> , 2004, 1, 185-196.	0.2	0
33	Expression, intracellular distribution and basis for lack of catalytic activity of the PDE4A7 isoform encoded by the human PDE4A cAMP-specific phosphodiesterase gene. <i>Biochemical Journal</i> , 2004, 380, 371-384.	1.7	24
34	Inhibition of angiotensin-converting enzyme and phosphodiesterase type 5 improves endothelial function in heart failure. <i>Clinical Science</i> , 2005, 108, 331-338.	1.8	42
35	Past, present, and future: a 7-year update of Viagra® (sildenafil citrate). <i>International Journal of Clinical Practice</i> , 2005, 59, 680-691.	0.8	70
36	A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. <i>Nature Biotechnology</i> , 2005, 23, 201-207.	9.4	220
37	Phosphodiesterase 5 and effects of sildenafil on cerebral arteries of man and guinea pig. <i>European Journal of Pharmacology</i> , 2005, 521, 105-114.	1.7	29

#	ARTICLE	IF	CITATIONS
38	Hemodynamic and Exercise Effects of Phosphodiesterase 5 Inhibitors. American Journal of Cardiology, 2005, 96, 32-36.	0.7	22
39	cGMP-dependent protein kinases in drug discovery. Drug Discovery Today, 2005, 10, 627-634.	3.2	69
40	Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications. Vascular Pharmacology, 2005, 42, 219-232.	1.0	184
41	Determination of caffeine and its metabolites in urine by capillary electrophoresis-mass spectrometry. Electrophoresis, 2005, 26, 2652-2663.	1.3	39
42	Expression and functional activity of phosphodiesterase type 5 in human and rabbit vas deferens. Molecular Human Reproduction, 2005, 11, 107-115.	1.3	77
43	Sildenafil: efficacy, safety, tolerability and mechanism of action in treating erectile dysfunction. Expert Opinion on Drug Metabolism and Toxicology, 2005, 1, 283-293.	1.5	37
44	Multiple Elements Jointly Determine Inhibitor Selectivity of Cyclic Nucleotide Phosphodiesterases 4 and 7. Journal of Biological Chemistry, 2005, 280, 30949-30955.	1.6	74
45	Characterization of the First Potent and Selective PDE9 Inhibitor Using a cGMP Reporter Cell Line. Molecular Pharmacology, 2005, 68, 1775-1781.	1.0	135
46	The Clinical Pharmacokinetics of Phosphodiesterase-5 Inhibitors for Erectile Dysfunction. Journal of Clinical Pharmacology, 2005, 45, 987-1003.	1.0	153
47	Phosphodiesterase-5 Inhibition: the Molecular Biology of Erectile Function and Dysfunction. Urologic Clinics of North America, 2005, 32, 419-429.	0.8	40
48	High lung PDE5: A strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochemical and Biophysical Research Communications, 2005, 334, 930-938.	1.0	190
49	Safety and Tolerability of Oral Erectile Dysfunction Treatments in the Elderly. Drugs and Aging, 2005, 22, 323-338.	1.3	7
50	Erectile Dysfunction Following Radical Retropubic Prostatectomy. Drugs and Aging, 2006, 23, 101-117.	1.3	48
51	Oral Therapy for Erectile Dysfunction. , 2006, , 271-286.		0
52	Enantiomer Discrimination Illustrated by the High Resolution Crystal Structures of Type 4 Phosphodiesterase. Journal of Medicinal Chemistry, 2006, 49, 1867-1873.	2.9	28
53	Phosphodiesterase-5 Inhibitor in Eisenmenger Syndrome. Circulation, 2006, 114, 1807-1810.	1.6	130
54	Synthesis, radiolabeling and in vivo evaluation of [11C]RAL-01, a potential phosphodiesterase 5 radioligand. Nuclear Medicine and Biology, 2006, 33, 593-597.	0.3	33
55	Loss of Sp1 function via inhibitory phosphorylation in antifolate-resistant human leukemia cells with down-regulation of the reduced folate carrier. Blood, 2006, 107, 708-715.	0.6	14

#	ARTICLE	IF	CITATIONS
56	Sildenafil improves cardiac output and exercise performance during acute hypoxia, but not normoxia. <i>Journal of Applied Physiology</i> , 2006, 100, 2031-2040.	1.2	124
57	Does the clinical efficacy of vardenafil correlate with its effect on the endothelial function of cavernosal arteries? A pilot study. <i>BJU International</i> , 2006, 98, 1054-1058.	1.3	13
58	Comparison of phosphodiesterase type 5 (PDE5) inhibitors. <i>International Journal of Clinical Practice</i> , 2006, 60, 967-975.	0.8	135
59	First-dose success with vardenafil in men with erectile dysfunction and associated comorbidities: RELY-I. <i>International Journal of Clinical Practice</i> , 2006, 60, 1378-1385.	0.8	30
60	Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 689-702.	21.5	471
61	Understanding the structure-activity and structure-selectivity correlation of cyclic guanine derivatives as phosphodiesterase-5 inhibitors by molecular docking, CoMFA and CoMSIA analyses. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 1462-1473.	1.4	41
62	Relaxant effect of sildenafil in the rabbit basilar artery. <i>Vascular Pharmacology</i> , 2006, 44, 10-16.	1.0	12
63	Feasibility of the Use of Phosphodiesterase Type 5 Inhibitors in a Pharmacologic Prevention Program for Recurrent Priapism. <i>Journal of Sexual Medicine</i> , 2006, 3, 1077-1084.	0.3	115
64	Extended Duration of Efficacy of Vardenafil When Taken 8 Hours Before Intercourse: A Randomized, Double-Blind, Placebo-Controlled Study. <i>European Urology</i> , 2006, 50, 1086-1095.	0.9	32
65	Effect of oral sildenafil citrate on intraoperative hemodynamics in patients with pulmonary hypertension undergoing valvular heart surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2006, 132, 1420-1425.	0.4	43
66	Multiple Conformations of Phosphodiesterase-5. <i>Journal of Biological Chemistry</i> , 2006, 281, 21469-21479.	1.6	137
67	Function of cGMP-Dependent Protein Kinases as Revealed by Gene Deletion. <i>Physiological Reviews</i> , 2006, 86, 1-23.	13.1	384
68	Structural insight into substrate specificity of phosphodiesterase 10. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 5782-5787.	3.3	110
69	Metabolic Risk Factors, Endothelial Dysfunction, and Erectile Dysfunction in Men With Diabetes. <i>American Journal of the Medical Sciences</i> , 2007, 334, 466-480.	0.4	15
70	The Molecular Basis for Different Recognition of Substrates by Phosphodiesterase Families 4 and 10. <i>Journal of Molecular Biology</i> , 2007, 371, 302-307.	2.0	52
71	Phosphodiesterase Type 5 Inhibitors: State of the Therapeutic Class. <i>Urologic Clinics of North America</i> , 2007, 34, 507-515.	0.8	27
72	Phosphodiesterases. , 2007, , 919-957.		6
73	Anterior ischemic optic neuropathy and stroke with use of PDE-5 inhibitors for erectile dysfunction: Cause or coincidence?. <i>Journal of the Neurological Sciences</i> , 2007, 262, 89-97.	0.3	32

#	ARTICLE	IF	CITATIONS
75	Sildenafil: A recent advance in the treatment of pulmonary arterial hypertension. <i>British Journal of Cardiac Nursing</i> , 2007, 2, 61-68.	0.0	0
76	Phosphodiesterase-5A and neutral endopeptidase activities in human adipocytes do not control atrial natriuretic peptide-mediated lipolysis. <i>British Journal of Pharmacology</i> , 2007, 152, 1102-1110.	2.7	40
77	Relaxation of human placental arteries and veins by ATP-sensitive potassium channel openers. <i>European Journal of Clinical Investigation</i> , 2007, 37, 65-72.	1.7	12
78	Diagnosis and management of erectile dysfunction in the primary care setting. <i>International Journal of Clinical Practice</i> , 2007, 61, 1198-1208.	0.8	19
79	Time-dependent involvement of cAMP and cGMP in consolidation of object memory: Studies using selective phosphodiesterase type 2, 4 and 5 inhibitors. <i>European Journal of Pharmacology</i> , 2007, 558, 107-112.	1.7	157
80	Nonurologic applications of phosphodiesterase type 5 inhibitors. <i>Current Sexual Health Reports</i> , 2007, 4, 64-70.	0.4	2
81	Highly stereoselective Pictet-Spengler reaction of d-tryptophan methyl ester with piperonal: convenient syntheses of Cialis (Tadalafil), 12a-epi-Cialis, and their deuterated analogues. <i>Tetrahedron: Asymmetry</i> , 2008, 19, 435-442.	1.8	50
82	Protective effects of sildenafil administration on testicular torsion/detorsion damage in rats. <i>World Journal of Urology</i> , 2008, 26, 197-202.	1.2	90
83	Dynamic structures of phosphodiesterase-5 active site by combined molecular dynamics simulations and hybrid quantum mechanical/molecular mechanical calculations. <i>Journal of Computational Chemistry</i> , 2008, 29, 1259-1267.	1.5	14
84	Sildenafil for pulmonary hypertension: Dose-dependent improvement in exercise performance. <i>Pulmonary Pharmacology and Therapeutics</i> , 2008, 21, 516-521.	1.1	8
85	Update on erectile dysfunction treatment for aging men. <i>Sexologies</i> , 2008, 17, 184-189.	0.5	2
86	Inhibition of phosphodiesterase type 5 with tadalafil is associated to an improved activity of circulating angiogenic cells in men with cardiovascular risk factors and erectile dysfunction. <i>Atherosclerosis</i> , 2008, 196, 313-319.	0.4	25
87	Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function. <i>International Journal of Impotence Research</i> , 2008, 20, 333-342.	1.0	41
88	Tadalafil in the treatment of erectile dysfunction. <i>Therapeutics and Clinical Risk Management</i> , 2008, Volume 4, 1315-1329.	0.9	86
90	Phosphodiesterase 5 Inhibition Improves Synaptic Function, Memory, and Amyloid- β Load in an Alzheimer's Disease Mouse Model. <i>Journal of Neuroscience</i> , 2009, 29, 8075-8086.	1.7	275
91	Safety, Efficacy, and Pharmacokinetic Overview of Low-Dose Daily Administration of Tadalafil. <i>Journal of Sexual Medicine</i> , 2009, 6, 2039-2048.	0.3	58
92	Evaluation of vardenafil for the treatment of subjective tinnitus: a controlled pilot study. <i>Journal of Negative Results in Biomedicine</i> , 2009, 8, 3.	1.4	27
93	Treatment of erectile dysfunction reduces psychological distress. <i>Journal of Developmental and Physical Disabilities</i> , 2009, 32, 74-80.	3.6	21

#	ARTICLE	IF	CITATIONS
94	Five-year experience with tadalafil in the UK: an effective treatment for erectile dysfunction. <i>International Journal of Clinical Practice</i> , 2009, 63, 1231-1236.	0.8	0
95	Differences in side-effect duration and related bother levels between phosphodiesterase type 5 inhibitors. <i>BJU International</i> , 2009, 103, 1392-1395.	1.3	51
96	Mouse sperm K ⁺ currents stimulated by pH and cAMP possibly coded by Slo3 channels. <i>Biochemical and Biophysical Research Communications</i> , 2009, 381, 204-209.	1.0	68
97	Zaprinast, a phosphodiesterase type-5 inhibitor, alters paced mating behavior in female rats. <i>Physiology and Behavior</i> , 2009, 96, 289-293.	1.0	14
98	Sildenafil decreased cardiac cell apoptosis in diabetic mice: reduction of oxidative stress as a possible mechanism. <i>Canadian Journal of Physiology and Pharmacology</i> , 2009, 87, 556-564.	0.7	28
99	Vardenafil Reduces Testicular Damage Following Ischemia/Reperfusion Injury in Rats. <i>Kaohsiung Journal of Medical Sciences</i> , 2009, 25, 374-380.	0.8	44
100	Identification of novel species-selective agonists of the G-protein-coupled receptor GPR35 that promote recruitment of β^2 -arrestin-2 and activate $G\beta 13$. <i>Biochemical Journal</i> , 2010, 432, 451-459.	1.7	91
101	Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: A single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers. <i>Clinical Therapeutics</i> , 2010, 32, 1178-1187.	1.1	62
102	Pharmacotherapy for Erectile Dysfunction. <i>Journal of Sexual Medicine</i> , 2010, 7, 524-540.	0.3	165
103	Target Profiling of a Small Library of Phosphodiesterase-5 (PDE5) Inhibitors using Chemical Proteomics. <i>ChemMedChem</i> , 2010, 5, 1927-1936.	1.6	17
104	Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: Safety, tolerability, and efficacy. <i>Drug, Healthcare and Patient Safety</i> , 2010, 2, 151.	1.0	22
105	An update on new oral PDE5 inhibitors for the treatment of erectile dysfunction. <i>Nature Reviews Urology</i> , 2010, 7, 603-609.	1.9	52
106	Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 1427-1437.	1.9	72
107	Protective effect of tadalafil on ischemia/reperfusion injury of rat ovary. <i>Journal of Pediatric Surgery</i> , 2010, 45, 2203-2209.	0.8	46
108	A Substrate Selectivity and Inhibitor Design Lesson from the PDE10 α 's cAMP Crystal Structure: A Computational Study. <i>Journal of Physical Chemistry B</i> , 2010, 114, 5154-5160.	1.2	5
109	Tadalafil. <i>Profiles of Drug Substances, Excipients and Related Methodology</i> , 2011, 36, 287-329.	3.5	15
110	Inhibition of Cyclic Nucleotide Phosphodiesterases by Methylxanthines and Related Compounds. <i>Handbook of Experimental Pharmacology</i> , 2011, , 93-133.	0.9	54
111	Newer Phosphodiesterase Inhibitors: Comparison with Established Agents. <i>Urologic Clinics of North America</i> , 2011, 38, 155-163.	0.8	12

#	ARTICLE	IF	CITATIONS
112	Farnesoid X receptor activation improves erectile dysfunction in models of metabolic syndrome and diabetes. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2011, 1812, 859-866.	1.8	17
113	Combined ligand based pharmacophore modeling, virtual screening methods to identify critical chemical features of novel potential inhibitors for phosphodiesterase-5. <i>Journal of the Taiwan Institute of Chemical Engineers</i> , 2011, 42, 709-718.	2.7	10
114	Antiplatelet therapy: phosphodiesterase inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 634-646.	1.1	236
115	Agonist activation of the G protein-coupled receptor GPR35 involves transmembrane domain III and is transduced via G_{i1} and β -arrestin2. <i>British Journal of Pharmacology</i> , 2011, 162, 733-748.	2.7	59
116	Efficacy and Safety of Once-Daily Dosing of Udenafil in the Treatment of Erectile Dysfunction: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. <i>European Urology</i> , 2011, 60, 380-387.	0.9	54
117	Use of a <i>Schizosaccharomyces pombe</i> PKA-repressible reporter to study cGMP metabolising phosphodiesterases. <i>Cellular Signalling</i> , 2011, 23, 594-601.	1.7	19
118	A state of art review on vardenafil in men with erectile dysfunction and associated underlying diseases. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1341-1348.	0.9	14
119	Effects of Vardenafil on Testicular Torsion/Detorsion Damage: An Experimental Study in Pigs. <i>Urologia Internationalis</i> , 2011, 86, 228-232.	0.6	15
121	An update view on the substrate recognition mechanism of phosphodiesterases: A computational study of PDE10 and PDE4 bound with cyclic nucleotides. <i>Biopolymers</i> , 2012, 97, 910-922.	1.2	2
122	Crystal engineering of multiple-component organic solids: Pharmaceutical cocrystals of tadalafil with persistent hydrogen bonding motifs. <i>CrystEngComm</i> , 2012, 14, 2377-2380.	1.3	32
123	Exploring the PDE5 H-pocket by ensemble docking and structure-based design and synthesis of novel β -carboline derivatives. <i>European Journal of Medicinal Chemistry</i> , 2012, 57, 329-343.	2.6	19
125	Chronic Low Dosing of Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction. <i>Korean Journal of Urology</i> , 2012, 53, 377.	1.2	8
126	Differential vasoactive effects of sildenafil and tadalafil on cerebral arteries. <i>European Journal of Pharmacology</i> , 2012, 674, 345-351.	1.7	18
127	Identification of chalcones as potent and selective PDE5A1 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 3983-3987.	1.0	5
128	Phosphodiesterase Inhibitors, Congestive Heart Failure, and Sudden Death: Time for Reevaluation. <i>Congestive Heart Failure</i> , 2012, 18, 229-233.	2.0	19
129	Icarisid II, a PDE5 inhibitor from <i>Epimedium wanshanense</i> , increases cellular cGMP by enhancing NOS in diabetic ED rats corpus cavernosum tissue. <i>Andrologia</i> , 2012, 44, 87-93.	1.0	35
130	Dose-dependent protective effect of sildenafil citrate on testicular injury after torsion/detorsion in rats. <i>Andrologia</i> , 2012, 44, 300-306.	1.0	20
131	Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial. <i>BJU International</i> , 2012, 110, 1801-1806.	1.3	44

#	ARTICLE	IF	CITATIONS
132	Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons. Arab Journal of Urology Arab Association of Urology, 2013, 11, 222-229.	0.7	30
133	Synthesis of quinoline derivatives: Discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2013, 60, 285-294.	2.6	96
134	The potent relaxant effect of resveratrol in rat corpus cavernosum and its underlying mechanisms. International Journal of Impotence Research, 2013, 25, 188-193.	1.0	15
135	NO/cGMP production is important for the endogenous peripheral control of hyperalgesia during inflammation. Nitric Oxide - Biology and Chemistry, 2013, 28, 8-13.	1.2	12
136	Malaria Parasite cGMP-dependent Protein Kinase Regulates Blood Stage Merozoite Secretory Organelle Discharge and Egress. PLoS Pathogens, 2013, 9, e1003344.	2.1	225
137	Erectile dysfunction "an update of current practice and future strategies. Journal of Clinical Urology, 2013, 6, 210-219.	0.1	6
138	Sildenafil and analogous phosphodiesterase type 5 (PDE-5) inhibitors in herbal food supplements sampled on the Dutch market. Food Additives and Contaminants - Part A Chemistry, Analysis, Control, Exposure and Risk Assessment, 2013, 30, 2027-2034.	1.1	29
139	Sildenafil citrate protects skeletal muscle of ischemia-reperfusion injury: immunohistochemical study in rat model. Acta Cirurgica Brasileira, 2013, 28, 282-287.	0.3	15
140	Udenafil for the treatment of erectile dysfunction. Therapeutics and Clinical Risk Management, 2014, 10, 341.	0.9	19
141	Mirodenafil for the Treatment of Erectile Dysfunction: A Systematic Review of the Literature. World Journal of Men's Health, 2014, 32, 18.	1.7	13
142	Different Role of cAMP Pathway on the Human Mast Cells HMC1 ⁺ and HMC1 ⁺ Activation. Journal of Cellular Biochemistry, 2014, 115, 896-909.	1.2	3
143	Multiplexed phosphospecific flow cytometry enables large-scale signaling profiling and drug screening in blood platelets. Journal of Thrombosis and Haemostasis, 2014, 12, 1733-1743.	1.9	29
144	Sildenafil Reduces Ischemia-Reperfusion Injury in Rat Ovary: Biochemical and Histopathological Evaluation. Gynecologic and Obstetric Investigation, 2014, 78, 162-167.	0.7	21
145	The effects of combined free radical scavenger and sildenafil therapy on age-associated erectile dysfunction: An animal model. Urology Annals, 2014, 6, 314.	0.3	7
146	Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS. Nature Reviews Urology, 2014, 11, 231-241.	1.9	34
147	Effects of tadalafil on ischemia/reperfusion injury in rat brain. Acta Neurologica Belgica, 2014, 114, 33-40.	0.5	4
148	Vardenafil Dihydrochloride. Profiles of Drug Substances, Excipients and Related Methodology, 2014, 39, 515-544.	3.5	10
149	Effect of the phosphodiesterase type 5 inhibitor tadalafil on pulmonary hemodynamics in a canine model of pulmonary hypertension. Veterinary Journal, 2014, 202, 334-339.	0.6	10

#	ARTICLE	IF	CITATIONS
150	Physical activity on endothelial and erectile dysfunction: a literature review. <i>Aging Male</i> , 2014, 17, 125-130.	0.9	39
151	Dose dependent protective effects of vardenafil on ischemia-reperfusion injury with biochemical and histopathologic evaluation in rat ovary. <i>Journal of Pediatric Surgery</i> , 2015, 50, 1205-1209.	0.8	16
152	Effects of tadalafil administration on plasma markers of exercise-induced muscle damage, IL6 and antioxidant status capacity. <i>European Journal of Applied Physiology</i> , 2015, 115, 531-539.	1.2	26
153	Preclinical pharmacokinetics of TPN729MA, a novel PDE5 inhibitor, and prediction of its human pharmacokinetics using a PBPK model. <i>Acta Pharmacologica Sinica</i> , 2015, 36, 1528-1536.	2.8	17
154	From canonical to non-canonical cyclic nucleotides as second messengers: Pharmacological implications. , 2015, 148, 154-184.		50
155	Development of a New Radiofluorinated Quinoline Analog for PET Imaging of Phosphodiesterase 5 (PDE5) in Brain. <i>Pharmaceuticals</i> , 2016, 9, 22.	1.7	15
157	A review of the efficacy and safety of mirodenafil in the management of erectile dysfunction. <i>Therapeutic Advances in Urology</i> , 2016, 8, 100-117.	0.9	9
158	Pharmacologic Therapy in Men's Health. <i>Medical Clinics of North America</i> , 2016, 100, 791-805.	1.1	4
159	Avanafil - a further step to tailoring patient needs and expectations. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1171-1181.	1.3	9
160	Pharmacotherapy for Erectile Dysfunction: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015). <i>Journal of Sexual Medicine</i> , 2016, 13, 465-488.	0.3	151
161	Luteinizing Hormone Causes Phosphorylation and Activation of the cGMP Phosphodiesterase PDE5 in Rat Ovarian Follicles, Contributing, Together with PDE1 Activity, to the Resumption of Meiosis1. <i>Biology of Reproduction</i> , 2016, 94, 110.	1.2	39
162	A Lipolytic Lecithin:Cholesterol Acyltransferase Secreted by Toxoplasma Facilitates Parasite Replication and Egress. <i>Journal of Biological Chemistry</i> , 2016, 291, 3725-3746.	1.6	48
163	Drugs for Treatment of Erectile Dysfunction. , 2016, , 783-800.		0
164	Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications. <i>Journal of Endocrinological Investigation</i> , 2016, 39, 143-151.	1.8	26
165	Influence of the PDE5 inhibitor tadalafil on redox status and antioxidant defense system in C2C12 skeletal muscle cells. <i>Cell Stress and Chaperones</i> , 2017, 22, 389-396.	1.2	26
166	Genetic Understanding of Stroke Treatment: Potential Role for Phosphodiesterase Inhibitors. <i>Advances in Neurobiology</i> , 2017, 17, 445-461.	1.3	10
167	Cardiac Immunomodulation. , 2017, , 681-714.		1
168	The protective effect of L-arginine, tadalafil, and their combination in rat testes after ischemia and reperfusion injury. <i>Canadian Urological Association Journal</i> , 2017, 11, 19.	0.3	14

#	ARTICLE	IF	CITATIONS
169	Luteinizing hormone signaling phosphorylates and activates the cyclic GMP phosphodiesterase PDE5 in mouse ovarian follicles, contributing an additional component to the hormonally induced decrease in cyclic GMP that reinitiates meiosis. <i>Developmental Biology</i> , 2018, 435, 6-14.	0.9	20
170	Sexual Dysfunction. <i>Medical Clinics of North America</i> , 2018, 102, 349-360.	1.1	2
171	Fluorometric detection of protein-ligand engagement: The case of phosphodiesterase5. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 149, 335-342.	1.4	6
172	An update on the drug safety of treating erectile dysfunction. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 965-975.	1.0	14
173	In vitro and in vivo evaluation of novel Tadalafil/ β 2-TCP/Collagen scaffold for bone regeneration: A rabbit critical-size calvarial defect study. <i>Biocybernetics and Biomedical Engineering</i> , 2019, 39, 789-796.	3.3	21
174	Synaptic and memory dysfunction induced by tau oligomers is rescued by up-regulation of the nitric oxide cascade. <i>Molecular Neurodegeneration</i> , 2019, 14, 26.	4.4	59
175	Coffee and Endothelial Function: A Coffee Paradox?. <i>Nutrients</i> , 2019, 11, 2104.	1.7	32
176	Phosphodiesterase 5 inhibitors as novel agents for the treatment of Alzheimer's disease. <i>Brain Research Bulletin</i> , 2019, 153, 223-231.	1.4	16
177	Nitric oxide-enhancing or -releasing agents as antithrombotic drugs. <i>Biochemical Pharmacology</i> , 2019, 166, 300-312.	2.0	56
178	The effect of surfactant and polymer on solution stability and solubility of tadalafil-methylparaben cocrystal. <i>Journal of Molecular Liquids</i> , 2019, 281, 86-92.	2.3	16
179	Pharmacodynamics of the agents used for the treatment of erectile dysfunction. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 121-131.	1.5	6
180	Role of application of tadalafil 5 mg once-daily (6 months) in men with erectile dysfunction from six randomized controlled trials. <i>Translational Andrology and Urology</i> , 2020, 9, 1405-1414.	0.6	3
181	Relaxation Effect of Patchouli Alcohol in Rat Corpus Cavernous and Its Underlying Mechanisms. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-11.	0.5	2
182	The Effect of Sildenafil on Selenite-Induced Cataract in Rats. <i>Current Eye Research</i> , 2020, 45, 1082-1088.	0.7	1
184	Effect of Tadalafil Administration on Redox Homeostasis and Polyamine Levels in Healthy Men with High Level of Physical Activity. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 9962.	1.2	3
185	Phosphodiesterase-5 Inhibition. , 2004, , 117-130.		2
186	Dipyridamole and PDE Inhibitors. , 2017, , 1283-1298.		3
187	Modulating cGMP to Treat Lung Diseases. <i>Handbook of Experimental Pharmacology</i> , 2009, , 469-483.	0.9	14

#	ARTICLE	IF	CITATIONS
188	Effect of icarisdil II on diabetic rats with erectile dysfunction and its potential mechanism via assessment of AGEs, autophagy, mTOR and the NO-cGMP pathway. Asian Journal of Andrology, 2013, 15, 143-148.	0.8	35
189	Structure, Catalytic Mechanism, and Inhibitor Selectivity of Cyclic Nucleotide Phosphodiesterases. , 2006, , .		2
190	Crystal Structure of Phosphodiesterase Families and the Potential for Rational Drug Design. , 2006, , .		2
191	Effects of sildenafil citrate on peripheral fatigue and exercise performance after exhaustive swimming exercise in rats. Journal of Exercise Rehabilitation, 2019, 15, 751-756.	0.4	11
192	Expression of Tas1 Taste Receptors in Mammalian Spermatozoa: Functional Role of Tas1r1 in Regulating Basal Ca ²⁺ and cAMP Concentrations in Spermatozoa. PLoS ONE, 2012, 7, e32354.	1.1	65
193	Sexual function in hypertensive patients receiving treatment. Vascular Health and Risk Management, 2006, 2, 447-455.	1.0	36
194	Co-Morbid Erectile Dysfunction (ED) and Antidepressant Treatment in a Patient - A Management Challenge?. Current Drug Targets, 2018, 20, 182-191.	1.0	6
195	Tadalafil treatment had a modest effect on endothelial cell damage and repair ability markers in men with erectile dysfunction and vascular risk. Asian Journal of Andrology, 2014, 16, 290.	0.8	7
196	Molecular processing of sildenafil in endothelial function: potential applications in cardiovascular diseases. , 2004, , 129-142.		0
197	Sildenafil, pharmacology of a highly selective PDE5 inhibitor. , 2004, , 15-33.		2
198	Oral Therapy for Erectile Dysfunction. , 2011, , 93-106.		11
199	Phosphodiesterase Inhibitors in the Treatment of Pulmonary Hypertension. , 2011, , 1477-1485.		1
200	Oral Prescription Therapy for Erectile Dysfunction. Contemporary Endocrinology, 2016, , 163-173.	0.3	1
201	Phosphodiesterase-5 Inhibitors. Handbook of Experimental Pharmacology, 2013, 218, 229-255.	0.9	5
202	Oral pharmacotherapy and the contemporary evaluation and management of erectile dysfunction. Reviews in Urology, 2003, 5 Suppl 7, S9-S20.	0.9	1
203	Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases. Experimental and Clinical Cardiology, 2011, 16, e30-5.	1.3	40
204	Evaluating the efficacy of intraplaque injection of dexamethasone with oral tadalafil in the chordee patients with Peyronie disease.. American Journal of Clinical and Experimental Urology, 2022, 10, 25-30.	0.4	0
205	Is sildenafil a doping drug in hypoxic conditions?. Aging Male, 2022, 25, 156-158.	0.9	1

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------